A Mini-Review on the Abuse of Psychotropic Substances in Malaysia
Abstract
Psychotropic substance use is a global issue that may pose unprecedented threats to nation-building and socioeconomic growth. The essential feature of substance use disorder (SUD) is a cluster of cognitive, behavioural and physiological symptoms indicating the individual continues to use the substances despite significant substance associated problems. Opioids, alcohol, cannabis, psychostimulants such as cocaine, amphetamine, and methamphetamine, as well as hallucinogens are among the substances that are commonly abused. Despite enormous efforts directed towards addressing the use of drugs or psychotropic substances use concerns, the cases associated with such use have increased significantly year after year. The transition from plant-based to synthetic drugs poses new challenges for drug policy and public health strategies in most of the countries including Malaysia. Furthermore, newly emerging drugs which include new psychoactive substances (NPSs) that recently spiked in the drug market, makes it increasingly difficult to tackle this problem. The purpose of this review was to summarize the existing literature on psychotropic substance use in Malaysia including drug treatment and rehabilitation program, identify challenges and provide directions for future research.
Downloads
References
Abidin, M. S. A. Z., Amin, M. Z. M., Salaeh, A., Yusoff, W. F. Z. W., & Fa’atin, S. (2022). The Practice of Islamic Psychospiritual Therapy in the Treatment of Drug Addiction at Rehabilitation Centres in Malaysia. Afkar: Jurnal Akidah dan Pemikiran Islam, 24(2), 143-168. https://doi.org/10.22452/afkar.vol24no2.4
Ahmad, M. A. (2025, February 19). Malaysia Terus Jadi Transit, 102 Tan Dadah Dirampas Sejan Mac 2024.Utusan Malaysia. https://www.utusan.com.my/nasional/2025/02/malaysia-terus-jadi-transit-102-tan-dadah-dirampas-sejak-mac-2024/#google_vignette
Amri, S., Salaeh, A., Mohd Amin M. Z., Adawiyah, R., Yahya M. (2019). The Role of Former Drug Abuser in the Management of Drug Treatment Center Using Psycho Spiritual Therapy in Malaysia and South Thailand: A Comparative Study. International Journal of Asian Social Science, 9(1),106-113. https://doi.org/10.18488/journal.1.2019.91.106.113.
Boyer, E. W., Babu, K. M., Adkins, J. E., McCurdy, C. R., & Halpern, J. H. (2008). Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction, 103(6), 1048–1050. https://doi.org/10.1111/J.1360-0443.2008.02209.X
Bertin, C., Montigne, E., Teixeira, S., Ferrer, F., Lauwerie, L., Richard, D., & Authier, N. (2023) Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected? Harm Reduction Journal, 20(1), 59. https://doi.org/10.1186/s12954-023-00781-2
Brose, W. G., Datta, D., & Kromelow, J. (2020). Clinical Use of Opioids for Chronic Pain. In: Noe, C. (Eds) Pain Management for Clinicians. (pp. 655–677). Springer, Cham. https://doi.org/10.1007/978-3-030-39982-5_21
Bryson, E. O. (2015). Novel Psychoactive Substances: Synthetic Cathinones and Cannabinoid Receptor Agonists In: Kaye, A., Kaye, A., Urman, R. (Eds) Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. (pp. 811–818). Springer New York. https://doi.org/10.1007/978-1-4614-8948-1_50
Chang-Chien, G. C., Odonkor, C. A., & Amorapanth, P. (2017). Is Kratom the New “Legal High” on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential. Pain Physician, 20(1). https://doi.org/10.36076/PPJ.2017.1.E195
Cherney, J. H., & Small, E. (2016). Industrial Hemp in North America: Production, Politics and Potential. Agronomy, 6(4), 58. https://doi.org/10.3390/AGRONOMY6040058
Colucci, S. V., Perrino, P. J., Shram, M. J., Bartlett, C., Wang, Y., & Harris, S. C. (2014). Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users. Clinical Drug Investigation, 34(6), 421–429. https://doi.org/10.1007/S40261-014-0192-3
Damiri, B., Mousa, A., & Helou, M. A. (2023). Amphetamine-type stimulant (ATS) use and association with concurrent use of benzodiazepines, barbiturates and THC in the West Bank among male Palestinians: a cross-sectional study. British Medical Journal Public Health, 1(1), e000537. https://doi.org/10.1136/bmjph-2023-000537
Damodaran, T., Chear, N. J. Y., Murugaiyah, V., Mordi, M. N., & Ramanathan, S. (2021). Comparative Toxicity Assessment of Kratom Decoction, Mitragynine and Speciociliatine Versus Morphine on Zebrafish (Danio rerio) Embryos. Frontiers in Pharmacology, 12, 714918. https://doi.org/10.3389/FPHAR.2021.714918
Dluzen, N. E., Darvesh, A. S., & Geldenhuys, W. J. (2012). Is Body Weight Loss a Harbinger of Methamphetamine-induced Neurotoxicity? J Addict Res Ther, 3(138), 2. http://doi.org/10.4172/2155-6105.1000138
Du, P., Liu, X., Zhong, G., Zhou, Z., Thomes, M. W., Lee, C. W., Bong, C.W., Zhang, X., Hao, F., Li, X., Zhang, G., & Thai, P. K. (2020). Monitoring Consumption of Common Illicit Drugs in Kuala Lumpur, Malaysia, by Wastewater-Cased Epidemiology. Int J Environ Res Public Health, 31, 17(3):889. https://doi.org/10.3390/ijerph17030889
Eastlack, S. C., Cornett, E. M., & Kaye, A. D. (2020). Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. Pain Therapy, 9(1), 55–69. https://doi.org/10.1007/S40122-020-00151-X
Edinoff, A. N., Kaufman, S. E., Mahoney, T. C., Upshaw, W. C., Gong, J. C., Cornett, E. M., Murnane, K. S., Kaye, A. M., Varrassi, G., Shekoohi, S., & Kaye, A. D. (2024). Kratom: A Narrative Review of the Possible Clinical Uses and Dangers of This Opioid-Like Plant. School of Medicine Faculty Publications, 3288. https://doi.org/10.7759/cureus.73058
Fernández, P. L. (2000). Potential therapeutic usefulness of cannabis and cannabinoids. Anales de La Real Academia Nacional de Medicina, 117(3), 595–624.
Fiellin, D. A., Friedland, G., & Gourevitch, M. N. (2006). Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases, 43(4), 173–177. https://doi.org/10.1086/508180
Götrick, B., Giglio, D., & Tobin, G. (2009). Effects of amphetamine on salivary secretion. European Journal of Oral Sciences, 117(3), 218–223. https://doi.org/10.1111/J.1600-0722.2009.00629.X
Gouzoulis-Mayfrank, E., & Daumann, J. (2009). Neurotoxicity of drugs of abuse-the case of methylenedioxy amphetamines (MDMA, ecstasy), and amphetamines. Dialogues in clinical neuroscience, 11(3), 305-317. https://doi.org/10.31887/DCNS.2009.11.3/egmayfrank
Graziano, S., Anzillotti, L., Mannocchi, G., Pichini, S., & Busardò, F. P. (2019). Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices. Journal of Pharmaceutical and Biomedical Analysis, 163, 170–179. https://doi.org/10.1016/j.jpba.2018.10.011
Greene, S. L., Kerr, F., & Braitberg, G. (2008). Review article: Amphetamines and related drugs of abuse. Emergency Medicine Australasia, 20(5), 391–402. https://doi.org/10.1111/J.1742-6723.2008.01114.X
Gu, C., Geng, Y., & Zhu, L. (2024). Dysregulation of dopamine neurotransmission in drug addicts: implications for criminal behavior and corrective interventions. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1434083
Harun, N., Johari, I. S., Mansor, S. M., & Shoaib, M. (2020). Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats. Psychopharmacology, 237(3), 855-867. https://doi.org/ 10.1007/s00213-019-05418-6
Hassan, R., Pike See, C., Sreenivasan, S., Mansor, S. M., Müller, C. P., & Hassan, Z. (2020). Mitragynine Attenuates Morphine Withdrawal Effects in Rats-A Comparison With Methadone and Buprenorphine. Frontiers in psychiatry, 11, 411. https://doi.org/10.3389/fpsyt.2020.00411
Ibrahim, F., & Kumar, N. (2009). The influence of community on relapse addiction to drug use: Evidence from Malaysia. Eur J Soc Sci, 11(3), 471-6.
Ismail, H., Ahmad, H. H., Sanef, A., Shahabudin, W., Reffin, N., Chan, D., Dawam, D., Hanan, F., Nordin, M., Sahar, L., Daud, K., Bongsu, K. T., Syezri, F., & Mustapa, H. (2023). The rising threat of illicit amphetamine-type stimulant use among methadone maintenance treatment patients in East Coast Malaysia: a retrospective observational study. American Journal of Drug and Alcohol Abuse, 49(1), 97–108. https://doi.org/10.1080/00952990.2022.2161051
Istiqomah, M. (2010). Amphetamines Type Stimulant (ATS) Production and Trafficking In Southeast Asia Countries. Risalah Hukum, 6(1), 46-55. https://e-journal.fh.unmul.ac.id/index.php/risalah/article/view/252
Jamalian, M., Nasrollahzadeh, M., Kazemifar, A. M., & Solhi, H. (2019). Comparing Methadone and Tincture of Opium for the Management of Opioid Withdrawal among Subjects with an Opioid Use Disorder. Journal of Pharmaceutical Research, 1–11. https://doi.org/10.9734/JPRI/2019/V31I630349
Karila, L., Petit, A., Cottencin, O., Coscas, S., & Reynaud, M. (2012). Synthetic drugs: the new low-cost landscape of drugs. La Revue Du Praticien, 62(5), 664–666.
Kaur, S., Sharma, N., & Roy, A. (2022). Role of Cannabinoids in Various Diseases: A Review. (2022). Current Pharmaceutical Biotechnology, 23(11), 1346–1358. https://doi.org/10.2174/1389201023666211223164656
Krabseth, H. M., Tuv, S. S., Strand, M. C., Karinen, R., Wiik, E., Vevelstad, M., Westin, A. A., Øiestad, E. L., & Vindenes, V. (2016). Novel psychoactive substances. Tidsskrift for Den Norske Laegeforening, 136(8), 714–717. https://doi.org/10.4045/TIDSSKR.15.1278
Kraft, K., Thomsen, M., & Schmidt, M. (2021). Cannabidiol: Food or Drug? A Positioning. Journal of Modern Medicinal Chemistry, 9, 17-24. https://doi.org/10.12970/2308-8044.2021.09.02
Kramer, J. C., Fischman, V. S., & Littlefield, D. C. (1967). Amphetamine abuse. Pattern and effects of high doses taken intravenously. JAMA, 201(5), 305–309. https://doi.org/10.1001/JAMA.201.5.305
Kulkarni, V. A., Nimje, H. P., Varhade, P. P., Chopade, R. K., Jatale, S. V., Mhaske, S. D., Nagrik, S. U., & Metangale, S. K. (2025). Cannabinoid pharmacology: Research on medicinal cannabins and its therapeutic application. Journal of Pharmaceutical and Biological Sciences, 12(2), 135–143. https://doi.org/10.18231/j.jpbs.2024.020
Kulsudjarit, K. (2004). Drug Problem in Southeast and Southwest Asia. Annals of the New York Academy of Sciences, 1025(1), 446–457. https://doi.org/10.1196/annals.1316.055
Larchenko, А. V., Suvorov, М. А., Andryukhin, V. I., Kaurov, Ya. V., & Suvorov, А. V. (2017). Synthetic Cathinones and Cannabinoids are New Psychoactive Substances (Review). Modern Technologies in Medicine, 9(1), 185-196. https://doi.org/10.17691/STM2017.9.1.23
Leonard, W., Zhang, P., Ying, D., & Fang, Z. (2020). Hempseed in food industry: Nutritional value, health benefits, and industrial applications. Comprehensive Reviews in Food Science and Food Safety, 19(1), 282–308. https://doi.org/10.1111/1541-4337.12517
Li, X., Ndungu, P., Taneja, S. B., Chapin, M. R., Egbert, S. B., Akenapalli, K., Paine, M. F., Kane-Gill, S. L., & Boyce, R. D. (2023). An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021. Clinical and Translational Science, 16(6), 1002–1011. https://doi.org/10.1111/cts.13505
Li, Y., Kong, D., Bi, K. X., & Luo, H. (2022). Related Effects of Methamphetamine on the Intestinal Barrier via Cytokines, and Potential Mechanisms by Which Methamphetamine May Occur on the Brain-Gut Axis. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.783121
Lindekamp, N., Weigel, S., Sachse, B., Schäfer, B., Rohn, S., & Triesch, N. (2024). Comprehensive analysis of 19 cannabinoids in commercial CBD oils: concentrations, profiles, and safety implications. Journal Fur Verbraucherschutz Und Lebensmittelsicherheit- Journal of Consumer Protection and Food Safety, 9(3), 259-267. https://doi.org/10.1007/s00003-024-01513-9
Lipman, Z. M., & Yosipovitch, G. (2021). Substance use disorders and chronic itch. Journal of The American Academy of Dermatology, 84(1), 148–155. https://doi.org/10.1016/J.JAAD.2020.08.117
Malini, C., Shamsudin, A. F., & Wahab, N. A. (2019). Effectiveness of Methadone Maintenance Therapy (MMT) and Life Style Improvement among Opiate Dependent Patients Registered. Jurnal Sains Kesihatan Malaysia, 17(1), 51–56. https://doi.org/10.17576/JSKM-2019-1701-07
Maria, N., Kusumawardani, L. A., & Salahuddin, F. S. (2021). Pharmacological Intervention in Opioid Withdrawal Syndromes among Opioid Abusers. Indonesian Journal of Clinical Pharmacy, 10(4), 330-352.https://doi.org/10.15416/ijcp.2021.10.4.330
Marovino, E., Morgillo, A., Mazzarella, M., & Randazzo, M. F. (2022). Methadone: From Chronic Non-Oncological pain and primary Management Of Opioid Hyperalgesia to Disassuefaction Of Painkillers Abuse. Qeios Ltd. https://doi.org/10.32388/abg3zq.2
McAvoy, B. R. (2009). Methamphetamine—what primary care practitioners need to know. Journal of Primary Health Care, 1(3), 170–176. https://doi.org/10.1071/HC09170
McKetin, R., Kozel, N., Douglas, J., Ali, R., Vicknasingam, B., Lund, J., & Li, J. H. (2008). The rise of methamphetamine in Southeast and East Asia. Drug and alcohol review, 27(3), 220–228. https://doi.org/10.1080/09595230801923710
Mohd Nawawi, N. A. A., Othman, E. A., Mohd Nasir, F., Abdullah, K. A., & Baharudin, M. N. (2024). Drug addictions in Malaysia: a mini-review on drug types, rehabilitation centers and therapeutic programs. Journal of Ethnicity in Substance Abuse, 8, 1-13. https://doi.org/10.1080/15332640.2024.2336495
Moncrieff, J., Cohen, D., & Porter, S. (2013). The psychoactive effects of psychiatric medication: the elephant in the room. Journal of psychoactive drugs, 45(5), 409–415. https://doi.org/10.1080/02791072.2013.845328
Montiel Ishino, F. A., McNab, P. R., Gilreath, T. D., Salmeron, B., & Williams, F. (2020). A comprehensive multivariate model of biopsychosocial factors associated with opioid misuse and use disorder in a 2017-2018 United States national survey. BMC Public Health, 20(1), 1740. https://doi.org/10.1186/S12889-020-09856-2
Mustafa, N. S., Bakar, N. H. A., Mohamad, N., Adnan, L. H. M., Fauzi, N. F. A. M., Thoarlim, A., Omar, S. H. S., Hamzah, M. S., Yusoff, Z., Jufri, M., & Ahmad, R. (2020). MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity. Basic and clinical neuroscience, 11(4), 381–388. https://doi.org/10.32598/bcn.9.10.485
National Anti-Drugs Agency (NADA). (2024) Statistic Trend of Number of Drug Addicts Detected According to Type of Drugs, 2018–2024. National Anti-Drugs Agency (NADA). Retrieved from https://www.aadk.gov.my/en/drugs-statistics/
Nazari, A.-M., Hojjat, S. K., Khalili, M. N., Akbari, H., Khorrami, M., Akbarzadeh, M., & Kaviyani, F. (2023). The Survey of Prevalence and Content of Hallucinations and Delusions in Methamphetamine Dependents. International Journal of High Risk Behaviors and Addiction, 12(2). https://doi.org/10.5812/ijhrba-134015
Opheim, A., Gaulen, Z., Gaulen, Z., Solli, K. K., Solli, K. K., Latif, Z.-E.-H., Fadnes, L. T., Fadnes, L. T., Benth, J. S., Benth, J. S., Kunøe, N., Tanum, L., & Tanum, L. (2021). Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. American Journal on Addictions, 30(5), 453–460. https://doi.org/10.1111/AJAD.13151
Othman, Z. (2004). Myanmar, illicit drug trafficking and security implications. Akademika, 65(1), 27-43.
Passaro, R. C., Pandhare, J., Qian, H. Z., & Dash, C. (2015). The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology, 10(3), 477–486. https://doi.org/10.1007/s11481-015-9604-2
Pedersen, C. J., Wickersham, J. A., Altice, F. L., Kamarulzaman, A., Khoshnood, K., Gibson, B. A., Khati, A., Maviglia, F., & Shrestha, R. (2022). Prevalence and Correlates of Active Amphetamine-Type Stimulant Use Among Female Sex Workers in Malaysia. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.879479
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. https://doi.org/10.1038/SJ.BJP.0707442
Presti, D.E. (2012). Drugs, the Brain, and Behavior. In: Ramachandran, V.S. (Eds) Encyclopedia of Human Behavior. (2nd Ed., pp. 724-731). Academic Press. https://doi.org/10.1016/B978-0-12-375000-6.00138-5.
Prevete, E., Catalani, V., Singh, D., Kuypers, K. P. C., Theunissen, E. L., Townshend, H., Banayoti, H., Ramaekers, J. G., Pasquini, M., & Corazza, O. (2023). A Preliminary Inventory of Kratom (Mitragyna Speciosa) Products and Vendors on the Darknet and Cryptomarkets. Journal of Psychoactive Drugs, 1–11. https://doi.org/10.1080/02791072.2023.2242361
Ramanathan, S., & McCurdy, C. R. (2020). Kratom (Mitragyna speciosa): worldwide issues. Current Opinion in Psychiatry, 33(4), 312–318. https://doi.org/10.1097/YCO.0000000000000621
Ramanathan, S., León, F., Chear, N. J. Y., Yusof, S. R., Murugaiyah, V., McMahon, L. R., & McCurdy, C. R. (2021). Kratom (Mitragyna speciosa Korth.): A description on the ethnobotany, alkaloid chemistry, and neuropharmacology. Studies in natural products chemistry, 69, 195-225. https://doi.org/10.1016/B978-0-12-819487-4.00003-3
Rock, E. M., & Parker, L. A. (2021). Constituents of Cannabis Sativa. Cannabinoids and neuropsychiatric disorders, 1-13. https://doi.org/10.1007/978-3-030-57369-0_1
Rusydan, A. M., Lukitaningsih, E., & Fakhrudin, N. (2022). Mitragyna speciosa: Opioid Addiction Treatment and Risk of Use. JPSCR : Journal of Pharmaceutical Science and Clinical Research, 7(2), 238. https://doi.org/10.20961/jpscr.v7i2.50942
Sánchez, M. I., Guillen, S. C., Mena, M. J., & Altamirano, E. C. (2024). Analysis of the therapeutic basis of cannabis and its application in medicine. Salud, Ciencia y Tecnología, 4, 937-937.https://doi.org/10.56294/saludcyt2024937
Santos, I. C. S., Maia, D. C. B., Dinis‐Oliveira, R. J., & Barbosa, D. J. (2024). New Psychoactive Substances: Health and Legal Challenges. Psychoactives, 3(2), 285–302. https://doi.org/10.3390/psychoactives3020018
Sanvisens, A., Bolao, F., Vallecillo, G., Torrens, M., Fuster, D., Pérez-Hoyos, S., Tor, J., Rivas, I., & Muga, R. (2013). HIV Infection and Viral Hepatitis in Drug Abusers. Current Perspectives in HIV Infection. IntechOpen. https://doi.org/10.5772/53074
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020). New psychoactive substances: a review and updates. Therapeutic advances in psychopharmacology, 10, 2045125320967197. https://doi.org/10.1177/2045125320967197
Sharpe, L., Sinclair, J., Kramer, A., de Manincor, M., & Sarris, J. (2020). Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal of Translational Medicine, 18(1), 374. https://doi.org/10.1186/s12967-020-02518-2
Simpson, K. H., & McDonnell, E. (2007). Opioids in the management of persistent non-cancer pain. Anaesthesia & Intensive Care Medicine, 9(2), 51-54.
Singh, D., Müller, C. P., Vicknasingam, B., & Mansor, S. M. (2015). Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia. Journal of Psychoactive Drugs, 47(2), 125–131. https://doi.org/10.1080/02791072.2015.1012610
Sivanesan, E., Gitlin, M. C., & Candiotti, K. A. (2016). Opioid-induced Hallucinations: A Review of the Literature, Pathophysiology, Diagnosis, and Treatment. Anesthesia and Analgesia, 123(4), 836-43. https://doi.org/10.1213/ANE.0000000000001417
Soria Sanchez, M. L. (2017). New Psychoactive Substances: Risks and Challenges. Toxicology and Forensic Medicine, 2(2), 39–40. https://doi.org/10.17140/TFMOJ-2-117
Souza, J. D. S., Madruga, C. S., & Noto, C. (2023). Emerging synthetic cannabinoids and the risk of psychosis: a growing concern for public health. Brazilian Journal of Psychiatry, 45(4), 306-307.https://doi.org/10.47626/1516-4446-2023-0051
Soyka, M. (2017). Treatment of opioid dependence with buprenorphine: current update. Dialogues in Clinical Neuroscience, 19(3), 299–308. https://doi.org/10.31887/DCNS.2017.19.3/MSOYKA
Taha, D. S. I., & Dr. Saddam Ali Hadi. (2024). The Phenomenon of Drug and Psychotropic Substance Abuse - Traditional and Digital - Causes, Effects, Solutions. Journal of Contemporary Business Law & Technology: Cyber Law, Blockchain, and Legal Innovations, 1(9), 25–42. https://doi.org/10.61796/ejcblt.v1i9.1013
Taylor, O. D. (2015). Poly Substance Use in Methadone Maintenance Therapy (MMT) Patients. Journal of Human Behavior in The Social Environment, 25(8), 822–829. https://doi.org/10.1080/10911359.2015.1028260
Tolomeo, S., Steele, J. D., Ekhtiari, H., & Baldacchino, A. (2021). Chronic heroin use disorder and the brain: Current evidence and future implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 111, 110148. https://doi.org/10.1016/j.pnpbp.2020.110148
Uddin, Md. S., Sufian, M. A., Kabir, Md. T., Hossain, Md. F., Nasrullah, Md., Islam, I., Mamun, A. A., Islam, Md. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research and Therapy, 8(4), 1–12. https://doi.org/10.4172/2155-6105.1000330
Wesson, D. R. (2004). Buprenorphine in the Treatment of Opiate Dependence: Its Pharmacology and Social Context of Use in the U.S. Journal of Psychoactive Drugs, 36, 119–128. https://doi.org/10.1080/02791072.2004.10400047
Witkiewitz, K. & Marlatt, G.A. (2004). Relapse Prevention for Alcohol and Drug Problems. American Psychologist, 59, 224-235. https://doi.org/10.1037/0003-066X.59.4.224
Yates, J. R. (2024). Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets. Substance Abuse and Rehabilitation, 125-161. https://doi.org/10.2147/SAR.S431273
